课题基金 / 基金详情

Risk-Benefit Framework for Genetic Tests

Risk-Benefit Framework for Genetic Tests
基因测试的风险效益框架
批准号:
7864075
负责人:
DAVID L VEENSTRA
金额:
$32.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-30 至 2012-09-29

项目摘要

项目成果

DAVID L VEENSTRA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The tremendous technological advances in genetic analysis over the past decade present a significant, yet challenging, opportunity to improving the public's health through genomics. Most often the clinical utility of a genetic test is not well known or understood at the time of its availability to patients, and the paucity of data will be an ongoing issue. Perhaps as challenging, the evidence criteria for genetic tests and the approaches for evaluating their clinical utility are unclear, complicating the translational pathway for genomic technologies. Recently, there has been significant interest in the use of formal risk-benefit analysis in regulatory decision making for drugs and biologics. One such approach uses disease-based health outcomes modeling to project the effect of an intervention on the incidence of clinical events, life expectancy, and quality of life, as well as a range of likely outcomes. We propose this approach will be particularly useful for assessing genetic tests intended to influence health outcomes, and communicating the potential clinical benefits, harms, and uncertainty to providers and policy makers. The overall goal of this project is to develop a formal clinical risk- benefit framework to facilitate the translational pathway for genomic technologies using three case studies; the Specific Aims are as follows: (1) Develop a quantitative risk-benefit framework for evaluating the clinical utility of genetic tests in collaboration with stakeholder groups, utilizing warfarin pharmacogenomics as a case example; (2) Assess the generalizability of the framework by applying it to two additional case studies: a) Gene expression profiling in women with early stage breast cancer, and b) Factor V Leiden testing for pregnant women with clotting or adverse pregnancy outcomes; (3) Evaluate and optimize the utility of the risk-benefit framework via a consensus development process with stakeholder groups. This translational research project will 1) develop a framework for assessing the evidence and uncertainty of genetic test utility, 2) clarify the evidence base for three currently available tests, and 3) provide a tool for educating clinicians and decision makers about the potential benefits and harms of genetic testing. This approach will help accelerate the integration, utilization, and practice-based evidence development of genetic tests that pose low risk but offer plausible benefit, while discouraging the premature use of tests that pose significant health risks. 7. Project narrative This translational research project will help improve the public's health by 1) developing a framework for assessing the evidence and uncertainty of genetic test utility, 2) clarifying the evidence base for several currently available tests, and 3) providing a tool for educating clinicians and decision makers about the potential benefits and harms of genetic testing. This approach will accelerate the integration, utilization, and practice-based evidence development of genetic tests that pose low risk but offer plausible benefit, yet discourage the premature use of tests that pose significant health risks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Personalized Medicine Economics Research PriMER
  • 批准号:
    8738586
  • 项目类别:
  • 资助金额:
    $37.02万
  • 财政年份:
    2013
  • 负责人:
    DAVID L VEENSTRA
  • 依托单位:
Personalized Medicine Economics Research PriMER
  • 批准号:
    9334042
  • 项目类别:
  • 资助金额:
    $35.59万
  • 财政年份:
    2013
  • 负责人:
    DAVID L VEENSTRA
  • 依托单位:
Health Economics Common Fund Program
  • 批准号:
    9075627
  • 项目类别:
  • 资助金额:
    $14.58万
  • 财政年份:
    2013
  • 负责人:
    DAVID L VEENSTRA
  • 依托单位:
Personalized Medicine Economics Research PriMER
  • 批准号:
    8627852
  • 项目类别:
  • 资助金额:
    $41.3万
  • 财政年份:
    2013
  • 负责人:
    DAVID L VEENSTRA
  • 依托单位:
海外基金